Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease.

The researchers analyzed the Nashville Familial Prostate Cancer Study (NFPCS), in an investigation comparing men with prostate cancer, each from a separate family with a strong history of the disease, to screened men without a personal or family history of prostate cancer. They analyzed haplotypes at a location of chromosome 8 which has been tied to the origin of prostate and numerous additional cancers.

The study, published March 23 in Nature Communications, explains roughly 9% of prostate cancer heritability. One mutation increased risk as much as 22-fold. Another mutation increased risk 4-fold, and was observed even among men without a strong family history. It was also associated with an early age of diagnosis. The researchers identified 183 variants associated with HPC at genome-wide significance, including these and others that had not been previously reported.

“We’ve taken a comprehensive shotgun approach to investigate data at this (chromosome) location and have been able to deconstruct how it contributes to risk, including which of the haplotypes impact age of onset and also aggressiveness,” said the study’s senior author, Jeffrey R. Smith, MD, PhD, associate professor of Medicine.

“Almost 2,300 men of the NFPCS, each with a desire to help others, contributed,” Smith said. Data from a separate, even larger study of HPC by the International Consortium for Prostate Cancer Genetics confirmed observations.

The study is believed to be the first to identify haplotypes comprehensively from all associated genetic variants at a locus. The study introduces new methods for finding genetic variants most contributing to risk.

Read this article on Science Daily: Materials provided by Vanderbilt University Medical Center. Original written by Tom Wilemon. 


About California HIFU and Dr. Lazar

Dr. Lazar is part of Northern California Medical Associates (NCMA) and operates California HIFU in Santa Rosa. He is the medical director of HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU).Dr. Michael Lazar offers a HIFU Program in partnership with HIFU Prostate Services, LLC (HPS). HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). HIFU prostate treatments are performed at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport.

Call Dr. Lazar at (707) 546-5553 for more information and to learn if you qualify , or simply fill out and submit the online form here.